Biomarker challenges for immune checkpoint inhibitors in urothelial carcinoma

Nat Rev Urol. 2018 Oct;15(10):585-587. doi: 10.1038/s41585-018-0056-3.

Authors

Tom Powles¹, Laura Morrison²

Affiliations

¹ Barts Cancer Institute Experimental Medicine Centre, Queen Mary University of London St Bartholomew's Hospital, London, UK. Thomas.Powles@bartshealth.nhs.uk.
² Barts Cancer Institute Experimental Medicine Centre, Queen Mary University of London St Bartholomew's Hospital, London, UK.

PMID: 30030491
DOI: 10.1038/s41585-018-0056-3

No abstract available

MeSH terms

Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Agents / therapeutic use
B7-H1 Antigen / blood
Biomarkers
Carcinoma, Transitional Cell / blood
Carcinoma, Transitional Cell / drug therapy*
Humans
Nivolumab / therapeutic use
Programmed Cell Death 1 Receptor / blood
Treatment Outcome
Urologic Neoplasms / blood
Urologic Neoplasms / drug therapy*

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
B7-H1 Antigen
Biomarkers
Programmed Cell Death 1 Receptor
durvalumab
Nivolumab
atezolizumab
pembrolizumab
avelumab